Melodia Therapeutics Secures Key U.S. Patent for Novel DPP1 Inhibitor MLD-151
核心洞察
Melodia Therapeutics (搜索) received a U.S. patent covering MLD-151 (搜索), a structurally novel DPP1 (搜索) inhibitor designed to treat neutrophil-driven inflammatory diseases (搜索).
The compound features a distinct chemotype differentiated from existing DPP1 (搜索) inhibitors like brensocatib, potentially offering optimized potency, selectivity, and tissue distribution.
MLD-151 (搜索) is advancing toward IND submission with plans for Phase 1/Phase 2a clinical studies targeting diseases driven by excessive neutrophil activation.
Melodia Therapeutics (搜索) AG announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering MLD-151 (搜索), a structurally novel DPP1 (搜索) (Cathepsin C (搜索)) inhibitor that represents a potentially differentiated approach to treating neutrophil-driven inflammatory diseases (搜索). The Basel-based clinical-stage biotechnology company licensed the compound exclusively from partner Alivexis (搜索), Inc. in June 2024.
Novel Chemical Structure Differentiates MLD-151
The newly issued patent (U.S. Patent No. 12,522,593; International Application No. PCT/JP2023/021735), entitled "Azacycloalkyl Carbonyl Cyclic Amine Compound," covers a proprietary compound series held by Alivexis (搜索), Inc. and Astellas Pharma Inc. MLD-151 (搜索) is based on a structurally distinct chemotype that is clearly differentiated from earlier DPP1 (搜索) inhibitors built on dipeptidyl nitrile scaffolds.
This structural distinction from Brinsocatib (搜索) (brensocatib, INSMED) provides robust positioning for MLD-151 (搜索) outside of a crowded intellectual property landscape where follow-on close structural analogs of brensocatib may face patent-related constraints. The novel chemotype was designed to enable differentiated pharmacology, including the potential for optimized potency, selectivity, and tissue distribution.
Targeting Neutrophil-Mediated Tissue Damage
DPP1 (搜索) serves as the master regulator of neutrophil serine protease activation, a pathway strongly implicated in tissue damage across multiple chronic inflammatory conditions (搜索). By potently and selectively inhibiting DPP1, MLD-151 (搜索) is designed to suppress excessive neutrophil-mediated tissue destruction while preserving key antimicrobial functions.
Melodia believes these features support a best-in-class profile across multiple neutrophil-driven inflammatory diseases (搜索), positioning the compound as a potentially superior therapeutic option in this emerging drug class.
Clinical Development Timeline
Melodia is currently advancing MLD-151 (搜索) toward IND submission, with plans to initiate Phase 1/Phase 2a clinical studies in diseases driven by excessive neutrophil activation. The company has not disclosed specific timelines for these regulatory and clinical milestones.
"We are pleased to see this important U.S. patent granted, further strengthening the intellectual property supporting our lead program," said Jonathan Talbot, CEO of Melodia Therapeutics (搜索). "We believe the novel chemotype discovered by our partner Alivexis (搜索) positions the program uniquely within an increasingly competitive DPP1 (搜索) inhibitor landscape."
Strategic Partnership
The development program represents a collaboration between Melodia Therapeutics (搜索) and Tokyo-based Alivexis (搜索), Inc., a drug discovery company that leverages advanced network-based technologies to identify and develop novel therapeutic candidates. Alivexis discovered the DPP1 (搜索) inhibitor and continues to collaborate on the advancement of the program under the exclusive global licensing agreement established in June 2024.